间变性甲状腺癌中细胞生长抑制剂跨膜蛋白34（TMEM34）的下调。
Down-regulation of an inhibitor of cell growth, transmembrane protein 34 (TMEM34), in anaplastic thyroid cancer.
作者信息
Akaishi J, Onda M, Okamoto J, Miyamoto S, Nagahama M, Ito K, Yoshida A, Shimizu K
机构信息
Department of Molecular Biology, Institute of Gerontology. Nippon Medical School, Kawasaki 211-8533, Japan.
出版信息
J Cancer Res Clin Oncol. 2007 Apr;133(4):213-8. doi: 10.1007/s00432-006-0159-8. Epub 2006 Oct 28.
PURPOSE
Ansaplastic thyroid cancer (ATC) is one of the most lethal malignancies, but the carcinogenic mechanism of ATC has not been clarified. Recently, we performed a cDNA microarray analysis and identified transmembrane protein 34 (TMEM34) that down-regulated in anaplastic thyroid cancer cell lines (ACL)s as compared to normal thyroid tissues.
METHODS
To investigate the role of TMEM34 in ATC carcinogenesis, we examined expression levels of TMEM34 in ACLs as well as differentiated thyroid cancers (DTC)s and normal human tissues. To explore the effect of TMEM34 in ATC development, cell-growth assays with KTA2 cells were performed.
RESULTS
Expression of TMEM34 was down-regulated in all 11 ACLs, as compared to either normal thyroid tissues or cell lines derived from papillary or follicular thyroid cancers. TMEM34 was expressed ubiquitously in normal human tissues tested. Transfection of TMEM34 into KTA2 cells led to inhibition of cell growth.
CONCLUSIONS
Our findings suggest that TMEM34 might be a tumor suppressor gene, associated with the development of ATC from DTC.
目的
间变性甲状腺癌（ATC）是最致命的恶性肿瘤之一，但ATC的致癌机制尚未阐明。最近，我们进行了一项cDNA微阵列分析，并鉴定出与正常甲状腺组织相比，在间变性甲状腺癌细胞系（ACL）中表达下调的跨膜蛋白34（TMEM34）。
方法
为了研究TMEM34在ATC致癌过程中的作用，我们检测了TMEM34在ACL以及分化型甲状腺癌（DTC）和正常人体组织中的表达水平。为了探究TMEM34在ATC发生发展中的作用，我们用KTA2细胞进行了细胞生长试验。
结果
与正常甲状腺组织或源自乳头状或滤泡状甲状腺癌的细胞系相比，所有11个ACL中TMEM34的表达均下调。TMEM34在所检测的正常人体组织中普遍表达。将TMEM34转染到KTA2细胞中导致细胞生长受到抑制。
结论
我们的研究结果表明，TMEM34可能是一种肿瘤抑制基因，与DTC发展为ATC有关。
Zotero 插件